60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Código da empresaSXTP
Nome da Empresa60 Degrees Pharmaceuticals Inc
Data de listagemJul 12, 2023
CEODr. Ll S. Dow, Ph.D.
Número de funcionários3
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 12
Endereço1025 Connecticut Avenue Nw
CidadeWASHINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal20036
Telefone12023275422
Sitehttps://60degreespharma.com/
Código da empresaSXTP
Data de listagemJul 12, 2023
CEODr. Ll S. Dow, Ph.D.
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados